Retrospective analysis of clinicopathological characteristics and family history data of early-onset breast cancer: A single-institutional study of hungarian patients

Pathology and Oncology Research

Volumn 19, Issue 4, 2013, Pages 723-729

  Madaras, Lilla ^a   Baranyák, Zsuzsanna ^b   Kulka, Janina ^a   Szász, Attila Marcell ^a   Kovács, Attila ^a   Lan, Phan Huong ^a   Székely, Borbála ^a   Dank, Magdolna ^a   Nagy, Tibor ^c   Kiss, Orsolya ^a   Harsányi, László ^a   Barbai, Tamás ^a   Kenessey, István ^a   Tőkés, Anna Mária ^a,d  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b Ministry of Defence   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Breast cancer; Early onset; Family history

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR;

ADULT; AGE; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; FAMILY HISTORY; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HUNGARY; IMMUNOPHENOTYPING; MAJOR CLINICAL STUDY; ONSET AGE; OVARY CARCINOMA; QUESTIONNAIRE; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SURVIVAL; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGE OF ONSET; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FAMILY HEALTH; FEMALE; HUMANS; HUNGARY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84885178162     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-013-9635-z     Document Type: Article

References (31)

1. Tusnady G, Gaudi I, Rejto L, Kasler M, Szentirmay Z (2008) Survival chances of hungarian cancer patients in the national cancer registry. Magy Onkol 52:339-349
2. American Cancer Society Workshop on Breast Cancer Detection in Younger Women (1993) A current assessment. Proceedings. New York, February 1-2, 1993. Cancer 72(4 suppl):1428-1497
3. Paluch-Shimon S, Wolf I, Sadetzki S, Gluck I, Oberman B et al (2011) Association between very young age and adverse characteristics of breast cancer at presentation amongst Israeli women. Am J Clin Oncol 34:219-222
4. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL et al (1994) Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12:888-894
5. Fredholm H, Eaker S, Frisell J, Holmberg L, Fredriksson I et al (2009) Breast cancer in young women: poor survival despite intensive treatment. PLoS One 4:e7695
6. Aebi S, Gelber S, Castiglione-Gertsch M, Gelber RD, Collins J et al (2000) Is chemotherapy alone adequate for young women with oestrogen-receptor- positive breast cancer? Lancet 355:1869-1874
7. Kim K, Chie EK, Han W, Noh DY, Oh DY et al (2011) Age <40Years is an independent prognostic factor predicting inferior overall survival in patients treated with breast conservative therapy. Breast J 17:75-78
8. Bonnier P, Romain S, Charpin C, Lejeune C, Tubiana N et al (1995) Age as a prognostic factor in breast cancer: relationship to pathologic and biologic features. Int J Cancer 62:138-144
9. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G et al (2002) Very young women (<35 years) with operable breast cancer: features of disease at presentation. Ann Oncol 13:273-279
10. Lin CH, Lu YS, Huang CS, Kuo KT, Wang CC et al (2011) Prognostic molecular markers in women aged 35 years or younger with breast cancer: is there a difference from the older patients? J Clin Pathol 64:781-787
11. Abenhaim HA, Azoulay L, Holcroft CA, Bure LA, Assayag J et al (2012) Incidence, risk factors, and obstetrical outcomes of women with breast cancer in pregnancy. Breast J 18:564-568
12. Chun J, Pocock B, Joseph KA, El-Tamer M, Klein L et al (2009) Breast cancer risk factors in younger and older women. Ann Surg Oncol 16:96-99
13. Ford D, Easton DF, Stratton M, Narod S, Goldgar D et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689
14. Van Der Looij M, Szabo C, Besznyak I, Liszka G, Csokay B et al (2000) Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer 86:737-740
15. Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A et al (2008) Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet 45:425-431
16. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE et al (2002) BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 20:2701-2712
17. van Harssel JJ, van Roozendaal CE, Detisch Y, Brandao RD, Paulussen AD et al (2010) Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection. Fam Cancer 9:193-201
18. Hickey M, Peate M, Saunders CM, Friedlander M (2009) Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 15:323-339
19. Gaudet MM, Press MF, Haile RW, Lynch CF, Glaser SL, et al. (2011) Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat 130:587-597
20. Han W, Kim SW, Park IA, Kang D, Youn YK et al (2004) Young age: an independent risk factor for disease-free survival in women with operable breast cancer. BMC Cancer 4:82
21. Fodor J, Mozsa E, Zaka Z, Polgar C, Major T (2005) Local relapse in young (< or = 40 years) women with breast cancer after mastectomy or breast conserving surgery: 15-year results. Magy Onkol 49:205-208, 203
22. Claus EB, Risch NJ, Thompson WD (1990) Age at onset as an indicator of familial risk of breast cancer. Am J Epidemiol 131:961-972
23. Collaborative Group of Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358:1389-1399
24. Loman N, Johannsson O, Kristoffersson U, Olsson H, Borg A (2001) Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. J Natl Cancer Inst 93:1215-1223
25. Evans DG, Howell A, Ward D, Lalloo F, Jones JL et al (2011) Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 48:520-522
26. Jiang X, Castelao JE, Chavez-Uribe E, Fernandez Rodriguez B, Celeiro Munoz C et al (2012) Family history and breast cancer hormone receptor status in a Spanish cohort. PLoS One 7:e29459
27. van der Hage JA, Mieog JS, van de Velde CJ, Putter H, Bartelink H et al (2011) Impact of established prognostic factors and molecular subtype in very young breast cancer patients: pooled analysis of four EORTC randomized controlled trials. Breast Cancer Res 13:R68
28. Kheirelseid EA, Boggs JM, Curran C, Glynn RW, Dooley C et al (2011) Younger age as a prognostic indicator in breast cancer: a cohort study. BMC Cancer 11:383
29. Anders CK, Fan C, Parker JS, Carey LA, Blackwell KL et al (2011) Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes? J Clin Oncol 29:e18-e20
30. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA et al (2008) Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 26:3324-3330
31. Ahn SH, Son BH, Kim SW, Kim SI, Jeong J et al (2007) Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea-a report from the Korean Breast Cancer Society. J Clin Oncol 25:2360-2368